Format

Send to

Choose Destination
Clin Immunol. 2008 Nov;129(2):182-94. doi: 10.1016/j.clim.2008.07.025. Epub 2008 Sep 9.

Invariant natural killer T cells and immunotherapy of cancer.

Author information

1
Cancer Center Amsterdam, VUMC Institute for Cancer and Immunology, Division of Immune Therapy, Department of Medical Oncology, The Netherlands.

Abstract

Invariant CD1d restricted natural killer T (iNKT) cells are regulatory cells that express a canonical TCR-Valpha-chain (Valpha24.Jalpha18 in humans and Valpha14.Jalpha18 in mice) which recognizes glycolipid antigens presented by the monomorphic CD1d molecule. They can secrete a wide variety of both pro-inflammatory and anti-inflammatory cytokines very swiftly upon their activation. Evidence for the significance of iNKT cells in human cancer has been ambiguous. Still, the (pre-)clinical findings reviewed here, provide evidence for a distinct contribution of iNKT cells to natural anti-tumor immune responses in humans. Furthermore, clinical phase I studies that are discussed here have revealed that the infusion of cancer patients with ligand-loaded dendritic cells or cultured iNKT cells is well tolerated. We thus underscore the potential of iNKT cell based immunotherapy in conjunction with established modalities such as surgery and radiotherapy, as adjuvant therapy against carcinomas.

PMID:
18783990
DOI:
10.1016/j.clim.2008.07.025
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center